Technetium Tc-99m red blood cells

Identification

Summary

Technetium Tc-99m red blood cells is a diagnostic radiopharmaceutical agent used for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding.

Generic Name
Technetium Tc-99m red blood cells
DrugBank Accession Number
DB09493
Background

Technetium Tc-99m red blood cells is a radiopharmaceutical diagnostic agent that is intravenously administered to be used in blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding. It is clinically useful in early detection and localization of bleeding sites, and preoperative diagnosis of hemangioma 4,1. Autologous red blood cells are radiolabeled with sodium pertechnetate Tc 99m in the reaction vial. Radiolabeled red blood cells are re-injected intravenously into the patient for gamma scintigraphic imaging Label. It is suggested that in vitro labelling improves the heart-to-background ratio during imaging 2.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Technetium (99mTc) red blood cells
  • Technetium Tc 99m red blood cells
  • Technetium Tc 99m-labeled red blood cells
  • Technetium Tc-99m red blood cell
  • Technetium Tc-99m red blood cell human

Pharmacology

Indication

Indicated for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding Label.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Diagnostic agentGastrointestinal bleeding••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Technetium Tc-99m red blood cells are diagnostic agents that are distributed within the circulation to assess the vascular nature of hemangiomas and diagnosis of venous occlusion 3. Blood abnormalities can be detected during gamma scintigraphic imaging.

Mechanism of action

Autologous red blood cells (RBC) are collected from the patient and put into the reaction vial for radiolabeling, followed by anticoagulation with heparin or Anticoagulant Citrate Dextrose Solution (ACD). In the reaction vial, stannous ion diffuses across the RBC membrane and accumulates intracellularly. Sodium hypochlorite, which does not cross the RBC membrane, is then added to the reaction vial to oxidize the extracellular stannous ion. Finally, sodium pertechnetate Tc 99m is added to the oxidized reaction vial to diffuse across the red blood cell membrane and be reduced by the intracellular stannous ion. Upon reduction, Tc 99m cannot diffuse out of the RBC. Technetium Tc 99m-labeled red blood cells are injected again into the patient for gamma scintigraphic imaging Label.

Absorption

Not Available

Volume of distribution

Following intravenous injection, the technetium Tc 99m-labeled red blood cells distribute within the blood pool with an estimated volume of distribution of approximately 5.6% of bodyweight Label.

Protein binding

Of the total technetium Tc 99m retained in the whole blood pool 24 hours after administration, 95% remains bound to the red blood cells Label.

Metabolism
Not Available
Route of elimination

Approximately 25% of the injected dose is excreted in the urine in the first 24 hours Label.

Half-life

Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. The technetium Tc 99m is well retained in the blood pool with an estimated biological half-life of approximately 29 hours Label.

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or to determine the effects on male or female fertility Label.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
UltraTag RBCKit0.05 mg/9.5mgIntravenousMallinckrodt1991-06-102017-07-01US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
D8L75GM22O
CAS number
Not Available

References

General References
  1. Emslie JT, Zarnegar K, Siegel ME, Beart RW Jr: Technetium-99m-labeled red blood cell scans in the investigation of gastrointestinal bleeding. Dis Colon Rectum. 1996 Jul;39(7):750-4. [Article]
  2. Patrick ST, Glowniak JV, Turner FE, Robbins MS, Wolfangel RG: Comparison of in vitro RBC labeling with the UltraTag RBC kit versus in vivo labeling. J Nucl Med. 1991 Feb;32(2):242-4. [Article]
  3. Front D, Israel O, Groshar D, Weininger J: Technetium-99m-labeled red blood cell imaging. Semin Nucl Med. 1984 Jul;14(3):226-50. [Article]
  4. Polito E, Burroni L, Pichierri P, Loffredo A, Vattimo AG: Technetium tc 99m-labeled red blood cells in the preoperative diagnosis of cavernous hemangioma and other vascular orbital tumors. Arch Ophthalmol. 2005 Dec;123(12):1678-83. doi: 10.1001/archopht.123.12.1678. [Article]
PubChem Substance
347910455
RxNav
1729152
FDA label
Download (233 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
KitIntravenous0.05 mg/9.5mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at November 30, 2015 19:10 / Updated at February 03, 2022 06:26